Rivastigmine Patch, Extended Release
FDA Label NDC 70771-1949

The following Structured Product Label (SPL) was submitted to the FDA by Zydus Lifesciences Limited for the product Rivastigmine (NDC 70771-1949). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Package Label.Principal Display Panel

Rx only

NDC 70771-1949-7

Rivastigmine

Transdermal System

Each System Delivers 4.6 mg/24 hours

For Transdermal Use Only.

Contains 30 systems

4.6 mg/24 Hrs (Eb52b342 1672 42e7 Bb4c 9c8f1bce7fc3 01)

Rx only

NDC 70771-1950-7

Rivastigmine

Transdermal System

Each System Delivers 9.5 mg/24 hours

For Transdermal Use Only.

Contains 30 systems

9.5 mg/24 Hrs (Eb52b342 1672 42e7 Bb4c 9c8f1bce7fc3 02)

Rx only

NDC 70771-1951-7

Rivastigmine

Transdermal System

Each System Delivers 13.3 mg/24 hours

For Transdermal Use Only.

Contains 30 systems

13.3 mg/24 Hrs (Eb52b342 1672 42e7 Bb4c 9c8f1bce7fc3 03)

* Please review the disclaimer below.